Celera Grants Bayer Cancer Rx License; Retains Companions Dx Rights | GenomeWeb

NEW YORK (GenomeWeb News) – Celera today said that it has licensed exclusive worldwide rights to Bayer Schering Pharma for five cancer-related drug targets and associated in vivo diagnostic imaging.

The Alameda, Calif.-based molecular diagnostics firm said that it will retain in vitro diagnostic rights and will be able to develop and sell companion diagnostics specific to therapeutic compounds developed by Bayer under the deal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.